Atractylodes macrocephala III suppresses EMT in cervical cancer by regulating IGF2BP3 through ETV5
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Meixia Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Atractylodes, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Health Commission of the People's Republic of China.
Abstract (Originalsprache)
Atractylodes macrocephala III (ATL III), with anti‐inflammatory and antitumor effects, is the main compound of Atractylodes macrocephala . Whether ATL III has an effect on cervical cancer and the specific mechanism are still unclear. Here, we investigated the effects of ATL III on cervical cancer cells at different concentrations and found that ATL III downregulates insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3), which was found to be highly expressed in cervical cancer tissue by RNA‐Seq. In this study, we found that ATL III promotes apoptosis and regulates epithelial–mesenchymal transition (EMT) in cervical cancer cells (HeLa and SiHa cells) and that IGF2BP3 is a common target gene of ATL III in HeLa and SiHa cells. The expression level of IGF2BP3 in cervical cancer cells was proportional to their migration and invasion abilities. This was verified by transfection of cells with a small interfering RNA and an IGF2BP3 overexpression plasmid. After ATL III treatment, the migration and invasion abilities of cervical cancer cells were obviously reduced, but these effects were attenuated after overexpression of IGF2BP3. In addition, the transcription factor IGF2BP3 was predicted by the JASPAR system. After intersection with our sequencing results, we verified the promotional effect of ETV5 (ETS translocation variant 5) on IGF2BP3 and found that ALT III inhibited ETV5. In general, our research showed that ATL III inhibits the migration and invasion of cervical cancer cells by regulating IGF2BP3 through ETV5.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Gynecology and Obstetrics, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, China.
- Department of Gynecology and Obstetrics, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Gynecology and Obstetrics, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
ORCID-Profile: Meixia Wang
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Health Commission of the People's Republic of China
Zitieren
APA
Wang, M., Meng, J., Wang, H., Hu, H., & Hong, Y. (2024). Atractylodes macrocephala III suppresses EMT in cervical cancer by regulating IGF2BP3 through ETV5. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18081
Vancouver
Wang M, Meng J, Wang H, Hu H, Hong Y. Atractylodes macrocephala III suppresses EMT in cervical cancer by regulating IGF2BP3 through ETV5. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18081
BibTeX
@article{Wang2024,
author = {Wang, Meixia and Meng, Jingwen and Wang, Hongyun and Hu, Huijuan and Hong, Ying},
title = {Atractylodes macrocephala III suppresses EMT in cervical cancer by regulating IGF2BP3 through ETV5},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18081}
}
EUVIMED